BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

WITA GmbH Release: Helm Changes Hands At Biotech Company


10/19/2005 5:09:01 PM

Teltow, Germany. Dr. Hanns-Rüdiger Graack (46) and Dr. Thomas Pohl (46) have been appointed new Managing Directors of WITA GmbH. The company’s former CEO, Prof. Dr. Brigitte Wittmann-Liebold, will continue to advise the Wittmann Institute of Technology and Analysis of Biomolecules in the capacity of Senior Scientist. Wittmann-Liebold founded WITA GmbH, one of the first biotech startups in the Berlin-Brandenburg region of Germany, in 1992. The company performs proteome and protein analyses for customers.

Graack, a biochemist who has been working for WITA since 2002, will continue to be responsible for strategic development and marketing. As Commercial Manager of the company, he will sharpen the company’s international focus. After studying at universities in Kiel and Tübingen in Germany, Graack conducted research at several institutions, including the University of Florida in the USA, before did his doctorate at the Max Planck Institute for Molecular Genetics in Berlin. After holding several positions in the scientific sector in Bochum, Hamburg and Berlin (where he worked at the Free University), Graack was assigned to handle the business side of founding the company MediTarget GmbH, a spin-off of the Max Planck Institute for Infectious Biology in Berlin. At the same time, he completed the Executive MBA program at Steinbeis University in Berlin.

Pohl has been working for the company as R&D Director since 2001. As Scientific Manager he is responsible for its operative business. Like Graack, Pohl is a biochemist, studied in Tübingen, and did his doctorate at the Max Planck Institute for Molecular Genetics in Berlin. After obtaining his PhD he conducted research at the Salk Institute for Biological Studies in La Jolla, California (USA). The Max Planck Institute for Experimental Medicine in Göttingen and Benjamin Franklin University Hospital in Berlin were further stepping stones in his scientific career.

Contact:

Dr. Hanns-Rüdiger Graack, WITA GmbH, Teltow, Germany, Fon: +49-(0)-3328-3949-33, graack@wita.de

Abdruck honorarfrei, bitte Belegexemplar an 3QM _ Jörg Levermann · Stubenrauchstr. 83 · 15732 Eichwalde


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->